Lysophosphatidic Acid Acyltransferase β (LPAATβ) Promotes the Tumor Growth of Human Osteosarcoma

BACKGROUND Osteosarcoma is the most common primary malignancy of bone with poorly characterized molecular pathways important in its pathogenesis. Increasing evidence indicates that elevated lipid biosynthesis is a characteristic feature of cancer. We sought to investigate the role of lysophosphatidic acid acyltransferase β (LPAATβ, aka, AGPAT2) in regulating the proliferation and growth of human osteosarcoma cells. LPAATβ can generate phosphatidic acid, which plays a key role in lipid biosynthesis as well as in cell proliferation and survival. Although elevated expression of LPAATβ has been reported in several types of human tumors, the role of LPAATβ in osteosarcoma progression has yet to be elucidated. METHODOLOGY/PRINCIPAL FINDINGS Endogenous expression of LPAATβ in osteosarcoma cell lines is analyzed by using semi-quantitative PCR and immunohistochemical staining. Adenovirus-mediated overexpression of LPAATβ and silencing LPAATβ expression is employed to determine the effect of LPAATβ on osteosarcoma cell proliferation and migration in vitro and osteosarcoma tumor growth in vivo. We have found that expression of LPAATβ is readily detected in 8 of the 10 analyzed human osteosarcoma lines. Exogenous expression of LPAATβ promotes osteosarcoma cell proliferation and migration, while silencing LPAATβ expression inhibits these cellular characteristics. We further demonstrate that exogenous expression of LPAATβ effectively promotes tumor growth, while knockdown of LPAATβ expression inhibits tumor growth in an orthotopic xenograft model of human osteosarcoma. CONCLUSIONS/SIGNIFICANCE Our results strongly suggest that LPAATβ expression may be associated with the aggressive phenotypes of human osteosarcoma and that LPAATβ may play an important role in regulating osteosarcoma cell proliferation and tumor growth. Thus, targeting LPAATβ may be exploited as a novel therapeutic strategy for the clinical management of osteosarcoma. This is especially attractive given the availability of selective pharmacological inhibitors.

[1]  Yong Zhu,et al.  mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis , 2010, Medical oncology.

[2]  T. He,et al.  Insulin-like growth factor 2 (IGF2) potentiates BMP9-induced osteogenic differentiation and bone formation , 2010 .

[3]  R. Gorlick.  Current concepts on the molecular biology of osteosarcoma. , 2010, Cancer treatment and research.

[4]  T. He,et al.  Insulin-like Growth Factor 2 (IGF-2) Potentiates BMP-9-Induced Osteogenic Differentiation and Bone Formation , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  T. He,et al.  Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma , 2010, Clinical Cancer Research.

[6]  Kounosuke Watabe,et al.  Metabolic genes in cancer: their roles in tumor progression and clinical implications. , 2010, Biochimica et biophysica acta.

[7]  J. Menéndez.  Fine-tuning the lipogenic/lipolytic balance to optimize the metabolic requirements of cancer cell growth: molecular mechanisms and therapeutic perspectives. , 2010, Biochimica et biophysica acta.

[8]  E. Kleinerman,et al.  The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. , 2009, Cancer treatment and research.

[9]  T. He,et al.  Wnt antagonist SFRP3 inhibits the differentiation of mouse hepatic progenitor cells , 2009, Journal of cellular biochemistry.

[10]  T. He,et al.  BMP‐9‐induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/β‐catenin signalling , 2009, Journal of cellular and molecular medicine.

[11]  T. He,et al.  A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. , 2009, Stem cells and development.

[12]  T. He,et al.  Establishment and characterization of a new highly metastatic human osteosarcoma cell line , 2009, Clinical & Experimental Metastasis.

[13]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.

[14]  A. K. Agarwal,et al.  Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. , 2009, Cell metabolism.

[15]  T. He,et al.  Hey1 Basic Helix-Loop-Helix Protein Plays an Important Role in Mediating BMP9-induced Osteogenic Differentiation of Mesenchymal Progenitor Cells* , 2009, Journal of Biological Chemistry.

[16]  A. Montag,et al.  Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects , 2008, Laboratory Investigation.

[17]  T. He,et al.  S100A6 Expression and Function in Human Osteosarcoma , 2008, Clinical orthopaedics and related research.

[18]  T. He,et al.  Osteosarcoma Development and Stem Cell Differentiation , 2008, Clinical orthopaedics and related research.

[19]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[20]  Wei Jiang,et al.  Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing. , 2007, Gene.

[21]  K. Kinzler,et al.  A protocol for rapid generation of recombinant adenoviruses using the AdEasy system , 2007, Nature Protocols.

[22]  T. He,et al.  Osteosarcoma and Osteoblastic Differentiation: A New Perspective on Oncogenesis , 2007, Clinical orthopaedics and related research.

[23]  J. Melo,et al.  Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib , 2006, Clinical Cancer Research.

[24]  A. Burton.  LPAAT-β identifies aggressive ovarian cancer , 2006 .

[25]  B. Mitchell,et al.  Effect of lysophosphatidic acid acyltransferase-β inhibition in acute leukemia , 2006 .

[26]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[27]  Wenhua Zhang,et al.  Signaling functions of phosphatidic acid. , 2006, Progress in lipid research.

[28]  A. Montag,et al.  CCN1/Cyr61 Is Regulated by the Canonical Wnt Signal and Plays an Important Role in Wnt3A-Induced Osteoblast Differentiation of Mesenchymal Stem Cells , 2006, Molecular and Cellular Biology.

[29]  J. Singer,et al.  Substrate specificity of lysophosphatidic acid acyltransferase beta -- evidence from membrane and whole cell assays. , 2006, Journal of Lipid Research.

[30]  C. Heizmann,et al.  Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. , 2005, Cancer letters.

[31]  A. Hummer,et al.  Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies. , 2005, Cancer research.

[32]  J. Singer,et al.  Induction of Apoptosis Using Inhibitors of Lysophosphatidic Acid Acyltransferase-β and Anti-CD20 Monoclonal Antibodies for Treatment of Human Non-Hodgkin's Lymphomas , 2005, Clinical Cancer Research.

[33]  W. Weichert,et al.  Expression of lysophosphatidic acid acyltransferase beta (LPAAT-β) in ovarian carcinoma: correlation with tumour grading and prognosis , 2005, British Journal of Cancer.

[34]  K. Brown,et al.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. , 2005, Cancer research.

[35]  A. Montag,et al.  Connective Tissue Growth Factor (CTGF) Is Regulated by Wnt and Bone Morphogenetic Proteins Signaling in Osteoblast Differentiation of Mesenchymal Stem Cells* , 2004, Journal of Biological Chemistry.

[36]  J. Ioannidis,et al.  Prognostic Significance of TP53 Tumor Suppressor Gene Expression and Mutations in Human Osteosarcoma , 2004, Clinical Cancer Research.

[37]  J. Szatkowski,et al.  Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery , 2004, Gene Therapy.

[38]  K. Anderson,et al.  Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. , 2003, Cancer research.

[39]  P. Meltzer,et al.  Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Singer,et al.  Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis , 2003, Expert opinion on therapeutic targets.

[41]  A. Ball,et al.  Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells. , 2003, Molecular cancer therapeutics.

[42]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. , 2003, Cancer genetics and cytogenetics.

[43]  A. Montag,et al.  Cytoplasmic and/or nuclear accumulation of the β‐catenin protein is a frequent event in human osteosarcoma , 2002, International journal of cancer.

[44]  M. Rizzo,et al.  The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade , 2002, FEBS letters.

[45]  A. Montag,et al.  Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  Jie Chen,et al.  Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.

[47]  J. Papp,et al.  Identification of the gene altered in Berardinelli–Seip congenital lipodystrophy on chromosome 11q13 , 2001, Nature Genetics.

[48]  D. Leung.  The structure and functions of human lysophosphatidic acid acyltransferases. , 2001, Frontiers in bioscience : a journal and virtual library.

[49]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[50]  S. Kaste,et al.  Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis , 1999, Cancer.

[51]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[52]  H. Kimura,et al.  Prognosis of Osteosarcoma With Pulmonary Metastases at Initial Presentation Is Not Dismal , 1998, Clinical orthopaedics and related research.

[53]  A. Stamps,et al.  A human cDNA sequence with homology to non-mammalian lysophosphatidic acid acyltransferases. , 1997, The Biochemical journal.

[54]  M. Robbin,et al.  The many faces of osteosarcoma. , 1997, Radiographics : a review publication of the Radiological Society of North America, Inc.

[55]  L. Tjoelker,et al.  Human Lysophosphatidic Acid Acyltransferase , 1997, The Journal of Biological Chemistry.

[56]  A. Kumar,et al.  Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that enhance cytokine-induced signaling responses in cells. , 1997, DNA and cell biology.

[57]  R. Bell,et al.  Raf-1 Kinase Possesses Distinct Binding Domains for Phosphatidylserine and Phosphatidic Acid , 1996, The Journal of Biological Chemistry.

[58]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  K. HayGlass,et al.  Comparison of [3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. , 1995, Journal of immunological methods.

[60]  E. Holmes,et al.  Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[62]  M. Mison,et al.  Osteosarcoma , 1985, The Lancet.

[63]  J. Freeman,et al.  Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. , 2009, International journal of oncology.

[64]  A. Burton.  LPAAT-beta identifies aggressive ovarian cancer. , 2006, The Lancet Oncology.

[65]  B. Mitchell,et al.  Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia. , 2006, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[66]  R. Barakat,et al.  Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival. , 2006, Cancer.

[67]  R. Barakat,et al.  Lysophosphatidic acid acyltransferase‐β (LPAAT‐β) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival , 2006 .

[68]  A. Montag,et al.  An Orthotopic Model of Human Osteosarcoma Growth and Spontaneous Pulmonary Metastasis , 2005, Clinical & Experimental Metastasis.

[69]  J. Szatkowski,et al.  Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). , 2003, The Journal of bone and joint surgery. American volume.

[70]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[71]  R. Schneider-Stock,et al.  Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. , 1998, Pathology, Research and Practice.

[72]  F. Oberling,et al.  PCR RB gene studies in high grade osteosarcomas: Could it be a prognostic factor? , 1993 .